Evaluation of microRNA Gene Polymorphisms in Liver Transplant Patients with Hepatocellular Carcinoma

被引:1
|
作者
Dehbidi, Sahar [1 ]
Farokhizadeh, Zhaleh [1 ]
Karimi, Mohammad Hossein [2 ]
Afshari, Afsoon [2 ]
Behmanesh, Mehrdad [3 ]
Sanati, Mohammad Hossein [4 ]
Geramizadeh, Bita [2 ]
Yaghobi, Ramin [2 ]
机构
[1] Nour Danesh Inst Higher Educ, Fac Biol Sci, Dept Biol, Esfahan, Iran
[2] Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Shiraz, Iran
[3] Tarbiat Modares Univ, Fac Biol Sci, Dept Genet, Tehran, Iran
[4] Natl Inst Genet Engn & Biotechnol, Dept Med Genet, Tehran, Iran
关键词
Hepatocellular Carcinoma; MicroRNA; Liver Transplantation; Rejection; Polymorphism; TURKISH POPULATION; FUNCTIONAL POLYMORPHISM; EXPRESSION PATTERNS; HUMAN CANCER; ASSOCIATION; RISK; INFECTION; SUSCEPTIBILITY; MIR-499A-GREATER-THAN-G; CONTRIBUTES;
D O I
10.5812/hepatmon.102690
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Genetic polymorphism in the miRNA sequence might alter miRNA expression and/or maturation, which is associated with the development and progression of hepatocellular carcinoma (HCC) in liver transplant patients. Objectives: Therefore, the prevalence of miRNA-146a G > C (rs2910164), miRNA-499A > G (rs3746444), miRNA-149C > T (rs2292832), and miRNA-196a-2 C > T (rs11614913) gene polymorphisms was evaluated in liver recipients with HCC with or without experiencing graft rejection. Methods: In a cross-sectional study, tissue samples were collected from 60 HCC patients who underwent liver transplant surgery at Namazi Hospital, Shiraz, Iran, in 2013 - 2015. A control group consisting of 120 individuals was randomly selected, as well. The genomic DNA was extracted from collected tissues and blood samples. The miRNA-146a (rs2910164), miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) gene polymorphisms were evaluated in patients with HCC using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results: The CC genotype and C allele of the miRNA-146a (rs2910164) polymorphism were significantly associated with the increased risk of transplant rejection in patients with HCC (P = 0.05 and P = 0.05, respectively). The CC genotype and C allele of the miRNA-146a (rs2910164) were also significantly more frequent in male liver transplant patients who experienced acute rejection than in non-rejected ones (P = 0.05 and P = 0.03, respectively). However, no significant association was found between the genotypes and alleles of miRNA-499 (rs3746444), miRNA-149 (rs2292832), and miRNA-196a-2 (rs11614913) polymorphisms and HCC outcomes in liver transplant recipients. Conclusions: The importance of the CC genotype and C allele of the miRNA-146a (rs2910164) polymorphism in increasing the risk of transplant rejection was confirmed, but it needs further studies in larger populations.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [41] DAAs Therapy Before Liver Transplant In Patients With Hepatocellular Carcinoma And HCV Liver Disease
    Pascual, Sonia
    Irurzun, Javier
    Rodriguez, Maria
    Rodriguez, Gonzalo
    Bellot, Pablo
    Carnicer, Fernando
    Melgar, Paola
    Bernabe, Juan M.
    Alcazar, Candido
    Franco, Mariano
    Palazon, Jose Maria
    Lluis, Felix
    HEPATOLOGY, 2017, 66 : 876A - 876A
  • [42] Liver transplant candidates with hepatocellular carcinoma: A retrospective analysis of their evaluation and outcome.
    Yamashiki, N
    Kato, T
    Reddy, KR
    Sobhonslidsuk, A
    Nishida, S
    Levi, D
    Schiff, ER
    Tzakis, AG
    HEPATOLOGY, 2001, 34 (04) : 663A - 663A
  • [43] Changes in Liver Transplant Criteria for Hepatocellular Carcinoma
    Dekey Lhewa
    Neehar D. Parikh
    Current Hepatology Reports, 2017, 16 (1) : 33 - 38
  • [44] A 2020 update on liver transplant for hepatocellular carcinoma
    Finotti, Michele
    Vitale, Alessandro
    Volk, Michael
    Cillo, Umberto
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (10) : 885 - 900
  • [45] Microvascular Invasion in Hepatocellular Carcinoma and Liver Transplant
    Jakhete, Neha
    Saberi, Behnam
    Jonassaint, Naudia L.
    Cosar, Arif M.
    Luu, Harry
    Kim, Amy
    Anders, Robert A.
    Philosophe, Benjamin
    Cameron, Andrew M.
    Gurakar, Ahmet
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2016, 14 : 14 - 18
  • [46] Canadian liver transplant allocation for hepatocellular carcinoma
    Brahmania, Mayur
    Marquez, Vladimir
    Kneteman, Norman M.
    Bhat, Mamatha
    Marleau, Denis
    Wong, Philip
    Peletekian, Kevork M.
    Burak, Kelly W.
    Congly, Stephen E.
    JOURNAL OF HEPATOLOGY, 2019, 71 (05) : 1058 - 1060
  • [47] Sirolimus in Liver Transplant Recipients With Hepatocellular Carcinoma
    Grigg, Sam
    Gow, Paul
    Yeomans, Neville
    JOURNAL OF INVESTIGATIVE SURGERY, 2020, 33 (04) : 389 - 390
  • [49] Living Donor Liver Transplant for Hepatocellular Carcinoma
    Vijay Subramanian
    William Chapman
    Annals of Surgical Oncology, 2019, 26 : 1594 - 1595
  • [50] Expanded Criteria for Hepatocellular Carcinoma in Liver Transplant
    Haberal, Mehmet
    Akdur, Aydincan
    Moray, Gokhan
    Arslan, Gulnaz
    Ozcay, Figen
    Selcuk, Haldun
    Ozdemir, Handan
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2017, 15 : 55 - 58